Bumble Inc vs Cassava Sciences Inc — how do they compare? Bumble Inc trades at $2.63 (market cap $366.87M), while Cassava Sciences Inc trades at $0.95 (market cap $47.75M). The key difference: Bumble Inc is far larger — about 7.7× Cassava Sciences Inc's market cap. Which is the better fit depends on your goals.
| BMBL | FLNA | |
|---|---|---|
Market Cap | $366.87M | $47.75M |
Sector | Technology | Health |
52-Week High | $7.17 | $4.64 |
52-Week Low | $2.70 | $0.87 |
Enterprise Value | $672.73M | -$34.93M |
Signals from Pluang's Aura AI — not financial advice
BMBL trades at $2.73, down 3.53% on the day, with a bearish technical outlook. The company reported a Q2 2026 earnings miss and negative net income margin of -57.96%, though revenue of $965.66M in 2025 shows scale. Recent news highlights a major shift in its women-first messaging policy to boost engagement amid slowing growth and exploration of a potential sale.
The outlook is challenged by persistent losses and declining paying users, but a low P/S of 0.38 offers valuation appeal. Risks include execution of product changes and intense competition. Analysts are mostly neutral with a $3.62 price target, suggesting cautious optimism if turnaround efforts succeed.
FLNA trades at $0.9973, up 0.23% with a bearish technical signal despite recent earnings beats. The company shows negative profitability with ROE at -55.79% and ROA at -35.34%, though cash burn improved from -$33M to -$30M projected for 2026. Analyst consensus is strongly bullish with 8 buy ratings versus 4 hold ratings.
The outlook remains challenging due to persistent losses and negative cash flow, but analyst optimism and continued progress in TSC-related epilepsy therapies provide potential catalysts. Key risks include execution challenges in clinical development and the company's ability to secure additional funding.
Trailing returns across standard periods
Latest headlines on both assets
Bumble Inc is engaged in offering online dating services. The company operates two apps, Bumble and Badoo, where users come on a monthly basis to discover new people and connect with each other.
Read more on BMBL →Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →